Selected grade 3 to 4 toxicity comparison according to BMI group during induction
| Adverse event . | BMI <30 kg/m2 (n = 197) . | BMI 30-40 kg/m2 (n = 71) . | BMI ≥40 kg/m2 (n = 21) . | P . |
|---|---|---|---|---|
| CALGB 10403 (N = 289) | ||||
| Nonhematologic toxicity | 77.2% (152) | 80.3% (57) | 85.7% (18) | .685 |
| Hepatic toxicity | 31.0% (61) | 52.1% (37) | 61.9% (13) | .001 |
| Infection | 21.8% (43) | 26.8% (19) | 42.9% (9) | .092 |
| Alanine aminotransferase | 23.9% (47) | 35.2% (25) | 52.4% (11) | .009 |
| Aspartate aminotransferase | 7.1% (14) | 23.9% (17) | 28.6% (6) | <.0001 |
| Hyperbilirubinemia | 11.7% (23) | 31.0% (22) | 47.6% (10) | <.0001 |
| Pancreatitis | 2.0% (4) | 2.8% (2) | 9.5% (2) | .123 |
| Hyperglycemia | 26.4% (52) | 39.4% (28) | 47.6% (10) | .030 |
| Adverse event . | BMI <30 kg/m2 (n = 197) . | BMI 30-40 kg/m2 (n = 71) . | BMI ≥40 kg/m2 (n = 21) . | P . |
|---|---|---|---|---|
| CALGB 10403 (N = 289) | ||||
| Nonhematologic toxicity | 77.2% (152) | 80.3% (57) | 85.7% (18) | .685 |
| Hepatic toxicity | 31.0% (61) | 52.1% (37) | 61.9% (13) | .001 |
| Infection | 21.8% (43) | 26.8% (19) | 42.9% (9) | .092 |
| Alanine aminotransferase | 23.9% (47) | 35.2% (25) | 52.4% (11) | .009 |
| Aspartate aminotransferase | 7.1% (14) | 23.9% (17) | 28.6% (6) | <.0001 |
| Hyperbilirubinemia | 11.7% (23) | 31.0% (22) | 47.6% (10) | <.0001 |
| Pancreatitis | 2.0% (4) | 2.8% (2) | 9.5% (2) | .123 |
| Hyperglycemia | 26.4% (52) | 39.4% (28) | 47.6% (10) | .030 |
| . | BMI <30 kg/m2 (n = 124) . | BMI 30-40 kg/m2 (n = 25) . | BMI ≥40 kg/m2 (n = 9) . | P . |
|---|---|---|---|---|
| COG AALL0232 (N = 158) | ||||
| Nonhematologic toxicity | 62.1% (77) | 84.0% (21) | 55.6% (5) | .077 |
| Hepatic toxicity | 17.7% (22) | 40.0% (10) | 11.1% (1) | .042 |
| Infection | 18.6% (23) | 32.0% (8) | 55.6% (5) | .018 |
| Alanine aminotransferase | 15.3% (19) | 32.0% (8) | 11.1% (1) | 0.140 |
| Aspartate aminotransferase | 4.8% (6) | 8.0% (2) | 11.1% (1) | 0.394 |
| Hyperbilirubinemia | 4.0% (5) | 20.0% (5) | 11.1% (1) | .018 |
| Pancreatitis | 0% (0) | 8.0% (2) | 0% (0) | .046 |
| Hyperglycemia | 20.2 (25) | 32.0% (8) | 33.3% (3) | .303 |
| . | BMI <30 kg/m2 (n = 124) . | BMI 30-40 kg/m2 (n = 25) . | BMI ≥40 kg/m2 (n = 9) . | P . |
|---|---|---|---|---|
| COG AALL0232 (N = 158) | ||||
| Nonhematologic toxicity | 62.1% (77) | 84.0% (21) | 55.6% (5) | .077 |
| Hepatic toxicity | 17.7% (22) | 40.0% (10) | 11.1% (1) | .042 |
| Infection | 18.6% (23) | 32.0% (8) | 55.6% (5) | .018 |
| Alanine aminotransferase | 15.3% (19) | 32.0% (8) | 11.1% (1) | 0.140 |
| Aspartate aminotransferase | 4.8% (6) | 8.0% (2) | 11.1% (1) | 0.394 |
| Hyperbilirubinemia | 4.0% (5) | 20.0% (5) | 11.1% (1) | .018 |
| Pancreatitis | 0% (0) | 8.0% (2) | 0% (0) | .046 |
| Hyperglycemia | 20.2 (25) | 32.0% (8) | 33.3% (3) | .303 |
Number of patients is given in parentheses.